Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Pharma-Bio Serv (PBSV) over the last 17 years, with Q4 2025 value amounting to $347839.0.

  • Pharma-Bio Serv's Change in Receivables rose 48916.87% to $347839.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$203643.0, marking a year-over-year increase of 8602.26%. This contributed to the annual value of -$203643.0 for FY2025, which is 8602.26% up from last year.
  • As of Q4 2025, Pharma-Bio Serv's Change in Receivables stood at $347839.0, which was up 48916.87% from -$675376.0 recorded in Q3 2025.
  • In the past 5 years, Pharma-Bio Serv's Change in Receivables ranged from a high of $663696.0 in Q2 2023 and a low of -$1.6 million during Q1 2024
  • In the last 5 years, Pharma-Bio Serv's Change in Receivables had a median value of $85310.5 in 2024 and averaged -$88067.4.
  • Per our database at Business Quant, Pharma-Bio Serv's Change in Receivables skyrocketed by 66127.28% in 2021 and then tumbled by 418973.58% in 2025.
  • Quarter analysis of 5 years shows Pharma-Bio Serv's Change in Receivables stood at $471457.0 in 2021, then tumbled by 143.68% to -$205939.0 in 2022, then plummeted by 650.94% to -$1.5 million in 2023, then skyrocketed by 94.22% to -$89380.0 in 2024, then skyrocketed by 489.17% to $347839.0 in 2025.
  • Its Change in Receivables stands at $347839.0 for Q4 2025, versus -$675376.0 for Q3 2025 and -$62471.0 for Q2 2025.